Subtype-selective positron emission tomography imaging of poly ADP-ribose polymerase-1 binding in non-human primates, healthy volunteers, and patients with glioblastoma using [11C]AZ14193391
The novel PET radioligand, [11C]AZ14193391 enables subtype selective imaging of PARP1 binding. Its ability to image this protein in the human brain paves the way for accelerated research, diagnosis and drug development in neuro-oncology.
Authors
- Avipsa Ghosh (ORCID: https://orcid.org/0000-0003-3786-0453)
- Elisabetta Leo (ORCID: https://orcid.org/0000-0002-9761-8637)
- Nancy K. Mueller
- Anna D. Staniszewska (ORCID: https://orcid.org/0000-0003-1328-1959)
- Sabina Cosulich (ORCID: https://orcid.org/0000-0001-9666-0510)
- Petra Hamerlik
- Kenneth Dahl (ORCID: https://orcid.org/0000-0003-2948-2042)
- Per Stenkrona (ORCID: https://orcid.org/0000-0002-5529-3336)
- Antonia Högnäsbacka (ORCID: https://orcid.org/0000-0002-5258-6619)
- Massimo Squatrito (ORCID: https://orcid.org/0000-0002-4593-3790)
- Miguel A. Cortés González (ORCID: https://orcid.org/0000-0003-4299-8860)
- Peter Johnström (ORCID: https://orcid.org/0009-0007-9725-9172)
- Zsolt Cselényi (ORCID: https://orcid.org/0000-0002-8479-6282)
- Lars Farde (ORCID: https://orcid.org/0000-0003-1297-0816)
- R. F. Lawrence
- John G. Swales (ORCID: https://orcid.org/0000-0002-4792-0037)
- Aurelija Jučaitė (ORCID: https://orcid.org/0000-0002-2281-6436)
- Vasco C. Sousa (ORCID: https://orcid.org/0000-0002-0086-6168)
- Yasir Khani
- Andy Pike
- Giuseppe Stragliotto (ORCID: https://orcid.org/0000-0003-1968-6447)
- Jeffrey Johannes
- Magnus Schou
- Christer Halldin
- Barry Davies
- Jiri Bartek
Institutions
- AstraZeneca (United Kingdom) (GB)
- Karolinska Institutet (SE)
- AstraZeneca (South Korea) (KR)
- Translational Research in Oncology (FR)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Poland) (PL)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1093/neuonc/noaf290
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00